Rubius Therapeutics Nợ phải trả 2024

Rubius Therapeutics làm gì?

Rubius Therapeutics Inc is a US biotechnology company founded in 2013. The company's goal is to develop therapies based on artificially manufactured red blood cells, known as RBCs, to treat diseases for which effective treatment methods are currently unavailable. The idea for the creation of Rubius began with a discovery by Dr. Aviv Regev at the Broad Institute, a research institute in Cambridge, Massachusetts. She discovered a method for using artificially manufactured red blood cells to treat diseases. Rubius was launched to intensify research and development in this area and create groundbreaking therapies using a new technology. Rubius has a unique business model. The company relies on a novel development platform that focuses not on delivering drugs into cells, but on using red blood cells as a base. The technology enables the incorporation of special proteins or active ingredients into the RBCs' membrane. By selectively releasing these active ingredients into the bloodstream, diseases can be directly treated at their source. This approach offers many advantages, such as increased effectiveness and reduced side effects. Rubius is currently working on several product candidates in various clinical research programs. The company has three main areas of focus: immunology, rare diseases, and cancer. In the field of immunology, they are developing therapies for autoimmune diseases such as rheumatoid arthritis or multiple sclerosis. The company also has a pipeline of products that can be used for rare blood disorders like hemophilia. Additionally, Rubius is involved in cancer immunotherapy, aiming to combat cancer cells by targeted activation of the immune system. Rubius Therapeutics has already achieved successes, such as the approval of an RBC-based drug for sickle cell disease by the US Food and Drug Administration (FDA) in spring 2020. The first target molecule on the RBC surface refers to the C5b9 membrane attack complex, which can cause damage to red blood cells, inflammation, and damage to blood vessels. Rubius aims to incorporate a specific protein into the artificial red blood cells that blocks the attack on red blood cells by the C5b9 membrane attack complex. As a leader in the biotechnology industry, Rubius is an innovative company with a novel business model and promising technology. It is shaping the industry with various developments and revolutionizing therapy for serious diseases that previously lacked satisfactory treatment methods. Overall, Rubius is a promising company with great potential for the future. Rubius Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.